These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34418585)

  • 1. Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas.
    Wege H; Schulze K; von Felden J; Calderaro J; Reig M;
    Eur J Med Genet; 2021 Nov; 64(11):104313. PubMed ID: 34418585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
    Alshareefy Y; Shen CY; Prekash RJ
    Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome.
    Zhang C; Feng S; Tu Z; Sun J; Rui T; Zhang X; Huang H; Ling Q; Zheng S
    Cancer Med; 2021 Sep; 10(18):6227-6238. PubMed ID: 34331411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
    Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study.
    Short SS; Kastenberg ZJ; Wei G; Bondoc A; Dasgupta R; Tiao GM; Watters E; Heaton TE; Lotakis D; La Quaglia MP; Murphy AJ; Davidoff AM; Mansfield SA; Langham MR; Lautz TB; Superina RA; Ott KC; Malek MM; Morgan KM; Kim ES; Zamora A; Lascano D; Roach J; Murphy JT; Rothstein DH; Vasudevan SA; Whitlock R; Lal DR; Hallis B; Bütter A; Baertschiger RM; Lapidus-Krol E; Putra J; Tracy ER; Aldrink JH; Apfeld J; Le HD; Park KY; Rich BS; Glick RD; Fialkowski EA; Utria AF; Meyers RL; Riehle KJ
    Cancer; 2022 Jul; 128(14):2786-2795. PubMed ID: 35561331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology.
    Laohawetwanit T; Lerttanatum N; Wanpiyarat N; Manasilp N; Chaiparnich S
    Ann Diagn Pathol; 2021 Aug; 53():151770. PubMed ID: 34147845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
    Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
    Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
    [No Abstract]   [Full Text] [Related]  

  • 9. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Hepatocellular-Cholangiocarcinoma: Changes in the 2019 World Health Organization Histological Classification System and Potential Impact on Imaging-Based Diagnosis.
    Kim TH; Kim H; Joo I; Lee JM
    Korean J Radiol; 2020 Oct; 21(10):1115-1125. PubMed ID: 32729276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma.
    Sciarra A; Park YN; Sempoux C
    Hum Pathol; 2020 Feb; 96():48-55. PubMed ID: 31931021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
    Lee HS; Kim MJ; An C
    Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial.
    Fencer MG; Davis CH; Liu J; Galan MA; Spencer KR
    J Investig Med High Impact Case Rep; 2022; 10():23247096221129470. PubMed ID: 36541195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses.
    Morisue R; Kojima M; Suzuki T; Nakatsura T; Ojima H; Watanabe R; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Ishii G; Gotohda N; Fujiwara T; Ochiai A
    Int J Cancer; 2021 Aug; 149(3):546-560. PubMed ID: 33662146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments.
    Kassahun WT
    World J Surg Oncol; 2016 May; 14(1):151. PubMed ID: 27215576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological Features of Two Extremely Rare Hepatocellular Carcinoma Variants: a Brief Review of Fibrolamellar and Scirrhous Hepatocellular Carcinoma.
    Samdanci ET; Akatli AN; Soylu NK
    J Gastrointest Cancer; 2020 Dec; 51(4):1187-1192. PubMed ID: 32860202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
    Sia D; Villanueva A; Friedman SL; Llovet JM
    Gastroenterology; 2017 Mar; 152(4):745-761. PubMed ID: 28043904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma.
    Tang D; Nagano H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Monden M
    J Gastrointest Surg; 2006; 10(7):987-98. PubMed ID: 16843869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma.
    Granata V; Fusco R; Venanzio Setola S; Sandomenico F; Luisa Barretta M; Belli A; Palaia R; Tatangelo F; Grassi R; Izzo F; Petrillo A
    Radiol Oncol; 2020 May; 54(2):149-158. PubMed ID: 32463393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing.
    Jeon J; Maeng LS; Bae YJ; Lee EJ; Yoon YC; Yoon N
    Cancer Genomics Proteomics; 2018; 15(4):291-298. PubMed ID: 29976634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.